New drug combo aims to tame aggressive leukemia
NCT ID NCT05199051
Summary
This study is testing a combination of three drugs for adults with a specific type of acute myeloid leukemia (AML) that has returned after treatment or did not respond to initial therapy. The goal is to see if adding a newer targeted drug (gilteritinib) to two existing drugs is safe and can help control the disease and improve survival. The trial is for patients whose leukemia has a specific genetic change called an FLT3 mutation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHMS de Chambery
Chambéry, France
-
CHRU Nancy
Nancy, France
-
CHU Bordeaux
Bordeaux, France
-
CHU Limoges
Limoges, France
-
CHU d'Amiens
Amiens, France
-
CHU d'Angers
Angers, France
-
CHU de Caen
Caen, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier Universitaire de Nice
Nice, France
-
Centre Hospitalier de Versailles
Versailles, France
-
HIA Percy
Clamart, France
-
Hôpital Saint Louis
Paris, France
Conditions
Explore the condition pages connected to this study.